State Street Corp Has $52.19 Million Stock Position in Progyny, Inc. (NASDAQ:PGNY)

State Street Corp boosted its holdings in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 4.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,113,654 shares of the company's stock after purchasing an additional 134,861 shares during the quarter. State Street Corp owned about 3.66% of Progyny worth $52,185,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Point72 Asset Management L.P. boosted its position in shares of Progyny by 227.8% in the third quarter. Point72 Asset Management L.P. now owns 789,418 shares of the company's stock valued at $13,231,000 after acquiring an additional 548,602 shares during the period. Invenomic Capital Management LP acquired a new position in Progyny during the 3rd quarter valued at $29,509,000. Point72 Asia Singapore Pte. Ltd. boosted its holdings in Progyny by 2,283.8% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 36,544 shares of the company's stock valued at $612,000 after purchasing an additional 35,011 shares during the period. Erste Asset Management GmbH acquired a new stake in Progyny in the 3rd quarter worth $597,000. Finally, Edgestream Partners L.P. increased its holdings in shares of Progyny by 72.7% during the 3rd quarter. Edgestream Partners L.P. now owns 69,082 shares of the company's stock worth $1,158,000 after purchasing an additional 29,074 shares during the period. Institutional investors and hedge funds own 94.93% of the company's stock.

Progyny Price Performance

Shares of PGNY traded up $0.15 during trading hours on Friday, hitting $14.34. The stock had a trading volume of 6,060,792 shares, compared to its average volume of 1,424,908. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of 24.72, a P/E/G ratio of 1.64 and a beta of 1.35. The company's fifty day moving average is $15.39 and its two-hundred day moving average is $21.04. Progyny, Inc. has a 52 week low of $13.39 and a 52 week high of $42.08.

Progyny (NASDAQ:PGNY - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported $0.11 EPS for the quarter, missing analysts' consensus estimates of $0.37 by ($0.26). Progyny had a net margin of 5.03% and a return on equity of 11.36%. The firm had revenue of $286.63 million during the quarter, compared to analyst estimates of $296.85 million. During the same quarter last year, the firm earned $0.16 earnings per share. Progyny's quarterly revenue was up 2.0% on a year-over-year basis. Equities analysts predict that Progyny, Inc. will post 0.59 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. JMP Securities cut shares of Progyny from an "outperform" rating to a "market perform" rating in a research note on Thursday, September 19th. Bank of America reduced their price objective on Progyny from $22.00 to $21.00 and set a "buy" rating for the company in a research report on Wednesday, November 13th. Barclays decreased their price objective on Progyny from $30.00 to $17.00 and set an "overweight" rating on the stock in a report on Thursday, November 14th. Canaccord Genuity Group cut their target price on Progyny from $18.00 to $17.00 and set a "hold" rating for the company in a research note on Wednesday, November 13th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 price target on shares of Progyny in a research note on Tuesday, October 1st. Nine research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $25.00.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.